Disitamab Vedotin for Injection
Showing 1 - 25 of >10,000
Bladder Cancer Trial (Disitamab Vedotin for Injection,Penpulimab Injection)
Not yet recruiting
- Bladder Cancer
- Disitamab Vedotin for Injection,Penpulimab Injection
- (no location specified)
Aug 2, 2022
Radical Cystectomy, Urothelial Carcinoma Trial in Wuhan (Disitamab Vedotin and Gemcitabine)
Recruiting
- Radical Cystectomy
- Urothelial Carcinoma
- Disitamab Vedotin and Gemcitabine
-
Wuhan, Hubei, China
- +1 more
Feb 9, 2023
Cervical Cancer Trial in China (Disitamab Vedotin, Zimberelimab)
Not yet recruiting
- Cervical Cancer
- Disitamab Vedotin
- Zimberelimab
-
Bengbu, Anhui, China
- +11 more
Nov 23, 2023
Gastric Cancer Trial (Disitamab Vedotin Combined With Sintilimab)
Not yet recruiting
- Gastric Cancer
- Disitamab Vedotin Combined With Sintilimab
- (no location specified)
Jan 31, 2023
Gastric Cancer Trial in Beijing (RC48-ADC, Herceptin, Toripalimab)
Not yet recruiting
- Gastric Cancer
- RC48-ADC
- +4 more
-
Beijing, ChinaBeijing Cancer Hospital
Aug 7, 2023
Breast Cancer Trial in Xi'an (Disitamab Vedotin plus pyrotinib or naratinib)
Not yet recruiting
- Breast Cancer
- Disitamab Vedotin plus pyrotinib or naratinib
-
Xi'an, Shaanxi, ChinaXi'an International Medical Center Hospital
Aug 27, 2023
Gastric Cancer Trial (Disitamab Vedotin combined with Sintilimab)
Not yet recruiting
- Gastric Cancer
- Disitamab Vedotin combined with Sintilimab
- (no location specified)
Jul 2, 2023
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Capecitabine, oxaliplatin, Disitamab Vedotin)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Capecitabine
- +3 more
-
Beijing, Beijing, China
- +10 more
Nov 23, 2023
Breast Tumors Trial in Beijing, Nanjing, Changsha (Disitamab Vedotin, Toripalimab)
Not yet recruiting
- Breast Neoplasms
- Disitamab Vedotin
- Toripalimab
-
Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
- +2 more
Oct 23, 2023
RC48-ADC in Breast Cancer
Not yet recruiting
- Breast Cancer
- Disitamab vedotin
- (no location specified)
Apr 30, 2023
Gastric Cancer, HER2-low-expressing Gastric Cancer Trial in Shanghai (Disitamab Vedotin, Toripalimab)
Recruiting
- Gastric Cancer
- HER2-low-expressing Gastric Cancer
- Disitamab Vedotin
- Toripalimab
-
Shanghai, ChinaShanghai East Hospital
Oct 9, 2023
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48 Trial in Guanzhou (RC48+Tislelizumab+carboplatin,
Not yet recruiting
- Non Small Cell Lung Cancer
- +3 more
- RC48+Tislelizumab+carboplatin
- +2 more
-
Guanzhou, ChinaSunYat-senU
May 5, 2023
Breast Cancer Trial (Disitamab Vedotin+Anlotinib)
Not yet recruiting
- Breast Cancer
- Disitamab Vedotin+Anlotinib
- (no location specified)
Aug 14, 2023
HER2-positive Gastric Cancer, Immunotherapy Trial in Shanghai (Disitamab Vedotin combined with fruquintinib and Tislelizumab)
Recruiting
- HER2-positive Gastric Cancer
- Immunotherapy
- Disitamab Vedotin combined with fruquintinib and Tislelizumab
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 8, 2023
Urothelial Carcinoma Trial (disitamab vedotin, pembrolizumab, gemcitabine)
Not yet recruiting
- Urothelial Carcinoma
- disitamab vedotin
- +4 more
- (no location specified)
Jun 9, 2023
Advanced Breast Cancer Trial (Disitamab vedotin)
Not yet recruiting
- Advanced Breast Cancer
- Disitamab vedotin
- (no location specified)
Apr 16, 2023
Breast Cancer Trial in Chengdu (Disitamab Vedotin, Penpulimab)
Not yet recruiting
- Breast Cancer
- Disitamab Vedotin
- Penpulimab
-
Chengdu, Chengdu, Sichuan, China, ChinaWest China Hospital, Sichuan University
Feb 9, 2023
HER2, Colorectal Cancer Trial (Disitamab Vedotin Combined With Fruquintinib)
Not yet recruiting
- HER2
- Colorectal Cancer
- Disitamab Vedotin Combined With Fruquintinib
- (no location specified)
Dec 21, 2022
Solid Tumor Trial (Disitamab vedotin)
Not yet recruiting
- Solid Tumor
- Disitamab vedotin
- (no location specified)
Jul 10, 2023
Urothelial Carcinoma Trial (Disitamab Vedotin, radiotherapy)
Not yet recruiting
- Urothelial Carcinoma
- Disitamab Vedotin
- radiotherapy
- (no location specified)
Jun 20, 2023
Carcinoma, Squamous Cell of Head and Neck, NSCLC, Ovarian Tumors Trial (disitamab vedotin)
Not yet recruiting
- Carcinoma, Squamous Cell of Head and Neck
- +3 more
- disitamab vedotin
- (no location specified)
Aug 15, 2023
Gastric Cancer Trial (Disitamab Vedotin, Sintilimab, S-1)
Not yet recruiting
- Gastric Cancer
- Disitamab Vedotin
- +3 more
- (no location specified)
Nov 17, 2022
Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma Trial in Tianjin (Disitamab Vedotin Tislelizumab,
Recruiting
- Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
- Disitamab Vedotin Tislelizumab
- Disitamab Vedotin
-
Tianjin, Tianjin, ChinaTianjin Medical University Second Hospital
Aug 9, 2022
HR Positive/HER2 Low Expression Metastatic Breast Cancer Trial in Guangzhou, Shantou, Qionghai (Disitamab vedotin, Endocrine
Recruiting
- HR Positive/HER2 Low Expression Metastatic Breast Cancer
- Disitamab vedotin
- Endocrine therapy
-
Guangzhou, Guangdong, China
- +2 more
Jun 19, 2023